Abstract library

383 results for "adrenocortical cancer".
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes
Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect.
The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Erica Gentilin
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#1365 Exploring the Rising Incidence of Gastroenteropancreatic Neuroendocrine Tumors According to the Data from Regional Cancer Registry: A Population-Based Analysis of Epidemiology
Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is reported to arise worldwide. Similar tendency is observed in Bulgaria during the recent 6 years.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Paulina Vladova
#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Sergio Pedraza-Arévalo
#2154 Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer
Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Alexey Ivanov
#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Sara De Dosso
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.